Trial is approved for stem cell treatment for dry AMD

02/3/2012 | Wall Street Journal, The

The FDA is permitting StemCells to conduct a safety and efficacy trial of therapeutic candidate HuCNS-SC cells among patients with dry age-related macular degeneration, or AMD. Last year, testing of the adult stem cell treatment for a rare childhood brain disorder was halted because of a lack of qualified participants.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA